Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 10
Submit an article Journal homepage
139
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Pegylated interferon can control myelodysplastic/myeloproliferative syndrome with ring sideroblasts and thrombocytosis

Rudolf BenzDivision of Hematology and Oncology, Kantonsspital Muensterlingen, Muensterlingen, Switzerland; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0001-8198-6454
ORCID Icon,
Kathrin ZimmermannDepartment of Medical Oncology and Hematology, University Hospital of Zurich, Zurich, Switzerland;
,
Markus RechsteinerDeparment of Pathology, University Hospital of Zurich, Zurich, Switzerland
,
Stefan BalabanovDepartment of Medical Oncology and Hematology, University Hospital of Zurich, Zurich, Switzerland;
,
Markus G. ManzDepartment of Medical Oncology and Hematology, University Hospital of Zurich, Zurich, Switzerland;
&
Corinne C. WidmerDepartment of Medical Oncology and Hematology, University Hospital of Zurich, Zurich, Switzerland;
Pages 2533-2535 | Received 26 Mar 2020, Accepted 30 Apr 2020, Published online: 25 May 2020

References

  • Swerdlow SH, World Health Organization, International Agency for Research on Cancer. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. World Health Organization classification of tumours. Lyon: International Agency for Research on Cancer; 2017. p. 585.
  • Patnaik MM, Tefferi A. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: “2019 Update on Diagnosis, Risk-stratification, and Management”. Am J Hematol. 2019;94(4):475–488.
  • Broseus J, Florensa L, Zipperer E, et al. Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis. Haematologica. 2012;97(7):1036–1041.
  • Yacoub A, Mascarenhas J, Kosiorek H, et al. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood. 2019;134(18):1498–1509.
  • Masarova L, Patel KP, Newberry KJ, et al. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. Lancet Haematol. 2017;4(4):e165–e175.
  • Miller CA, McMichael J, Dang HX, et al. Visualizing tumor evolution with the fishplot package for R. BMC Genomics. 2016;17(1):880.
  • Bishop JB, Wassom JS. Toxicological review of busulfan (Myleran). Mutat Res. 1986;168(1):15–45.
  • Kiladjian J-J, Chevret S, Dosquet C, et al. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol. 2011;29(29):3907–3913.
  • Wagstaff AJ, Keating GM. Anagrelide: a review of its use in the management of essential thrombocythaemia. Drugs. 2006;66(1):111–131.
  • Tefferi A, Al-Kali A, Begna KH, et al. Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis. Blood Cancer J. 2016;6:e405.
  • Fenaux P, Kiladjian JJ, Platzbecker U. Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis. Blood. 2019;133(8):790–794.
  • Gunawan A, Harrington P, Garcia-Curto N, et al. Ruxolitinib for the treatment of essential thrombocythemia. Hemasphere. 2018;2(4):e56.
  • Stein BL, Tiu RV. Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms. J Interferon Cytokine Res. 2013;33(4):145–153.
  • Mullally A, Bruedigam C, Poveromo L, et al. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera. Blood. 2013;121(18):3692–3702.
  • Bowen D, Culligan D, Jowitt S, et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol. 2003;120(2):187–200.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.